Research programme: peptide antibacterials - SpiderBiotechAlternative Names: Peptide antibiotics - SpiderBiotech; SB-006; SB006-based antimicrobial peptides - SpiderBiotech; Tetrabranched antibacterial peptides - SpiderBiotech/NeED Pharmaceuticals
Latest Information Update: 16 Jul 2016
At a glance
- Originator SpiderBiotech
- Class Peptides
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Gram-negative infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Gram-negative-infections in Italy
- 22 Apr 2008 Antimicrobial & pharmacodynamic data from a preclinical trial in Gram-negative infections presented at the 18th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID-2008)
- 31 Dec 2005 Preclinical trials in Gram-negative infections in Italy (unspecified route)